Guardant Health (NASDAQ:GH) Insider Sells $977,865.39 in Stock

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 8,571 shares of Guardant Health stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the completion of the transaction, the insider owned 20,990 shares in the company, valued at $2,394,749.10. This trade represents a 28.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Guardant Health Stock Performance

GH stock opened at $114.75 on Friday. Guardant Health, Inc. has a one year low of $34.88 and a one year high of $120.74. The firm has a market cap of $14.46 billion, a price-to-earnings ratio of -35.75 and a beta of 1.58. The firm has a 50-day simple moving average of $105.24 and a two-hundred day simple moving average of $77.63.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09. The business’s revenue was up 38.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.88) EPS. As a group, equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on GH. Stifel Nicolaus boosted their target price on Guardant Health from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Barclays increased their price objective on shares of Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Wells Fargo & Company boosted their target price on shares of Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. BTIG Research raised their price target on shares of Guardant Health from $100.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Evercore ISI set a $105.00 price objective on shares of Guardant Health and gave the stock an “in-line” rating in a research note on Monday, January 5th. Twenty-one analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $102.81.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GH. Allworth Financial LP boosted its holdings in Guardant Health by 19.5% in the third quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after purchasing an additional 138 shares during the last quarter. Eastern Bank lifted its holdings in shares of Guardant Health by 6.9% in the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock valued at $221,000 after buying an additional 139 shares during the period. TD Waterhouse Canada Inc. boosted its stake in shares of Guardant Health by 3.2% in the third quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock worth $306,000 after buying an additional 151 shares during the last quarter. Signaturefd LLC grew its holdings in Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after acquiring an additional 213 shares during the period. Finally, GAMMA Investing LLC raised its position in Guardant Health by 38.8% during the fourth quarter. GAMMA Investing LLC now owns 808 shares of the company’s stock valued at $83,000 after acquiring an additional 226 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.